<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003763</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOCYTE-EC.OV.53.958</org_study_id>
    <secondary_id>CDR0000066889</secondary_id>
    <secondary_id>ENDOCYTE-96-286</secondary_id>
    <secondary_id>ENDOCYTE-98-0409</secondary_id>
    <nct_id>NCT00003763</nct_id>
  </id_info>
  <brief_title>Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer</brief_title>
  <official_title>A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endocyte</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endocyte</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be
      effective in detecting ovarian cancer.

      PURPOSE: Diagnostic trial to study the effectiveness of radiolabeled folic acid plus imaging
      in detecting ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the effectiveness of folic acid conjugated with indium In 111 to
      diagnose ovarian cancer and locate metastatic disease.

      OUTLINE: This is a diagnostic study. Patients receive an injection of folic acid conjugated
      with indium In 111. The patient then undergoes imaging studies at various time points (e.g.,
      1, 4, and 24 hours). Patients then undergo exploratory surgery, the results of which are then
      compared to the imaging studies.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 folic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Suspected ovarian cancer OR Recurrence of ovarian cancer Scheduled
        for exploratory surgery

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:
        Not specified Hematopoietic: WBC at least 3000/mm3 Granulocyte count at least 1500/mm3
        Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no
        greater than 2.0 mg/dL SGPT and SGOT no greater than 2 times upper limit of normal (ULN)
        Alkaline phosphatase no greater than 2 times ULN No acute hepatitis Renal: Creatinine no
        greater than 1.4 mg/dL BUN no greater than 1.5 times ULN No known or suspected kidney
        disease Cardiovascular: No history of congestive heart failure No unstable angina No
        myocardial infarction within 6 months Other: Not pregnant or nursing No septicemia or
        severe infection No medical condition that would preclude the administration of large fluid
        volumes over a short period of time

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 months
        since prior cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: At least
        3 months since prior radiotherapy Surgery: See Disease Characteristics Other: At least 2
        days since prior folic acid supplements At least 5 days since nonsteroidal antiinflammatory
        medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Gershenson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University - St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2004</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>stage I ovarian germ cell tumor</keyword>
  <keyword>stage II ovarian germ cell tumor</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
  <keyword>ovarian sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

